Pomerantz Law Firm Launches Investigation into Novartis AG for Alleged Securities Fraud#United_States#New_York#Securities_Fraud#Pomerantz_LLP#Novartis_AG
Pomerantz Law Firm Launches Investigation into Novartis AG for Alleged Securities Fraud
Pomerantz LLP is investigating possible securities fraud claims related to Novartis AG following a significant stock price drop. Investors are urged to act.
third-news.com
October 1, 2026 at 2:49 PM
Pomerantz Law Firm Launches Investigation into Novartis AG for Alleged Securities Fraud#United_States#New_York#Securities_Fraud#Pomerantz_LLP#Novartis_AG
Avidity Biosciences Plans to Postpone and Reconvene Stockholder Meeting amid Upcoming Merger#San_Diego#Avidity_Biosciences#Novartis_AG#RNA
Avidity Biosciences Plans to Postpone and Reconvene Stockholder Meeting amid Upcoming Merger
Avidity Biosciences announces plan to adjourn its special stockholder meeting and convene again on February 26, 2026, for merger proceedings.
third-news.com
February 23, 2026 at 1:26 PM
Avidity Biosciences Plans to Postpone and Reconvene Stockholder Meeting amid Upcoming Merger#San_Diego#Avidity_Biosciences#Novartis_AG#RNA
Investigation Launched into Avidity Biosciences' Proposed Sale to Novartis AG#United_States#New_York#Monteverde_Associates#Avidity_Biosciences#Novartis_AG
Investigation Launched into Avidity Biosciences' Proposed Sale to Novartis AG
Monteverde & Associates PC has announced an investigation into Avidity Biosciences Inc. regarding its planned sale to Novartis AG, focusing on the fairness of the deal.
third-news.com
October 27, 2025 at 9:45 PM
Investigation Launched into Avidity Biosciences' Proposed Sale to Novartis AG#United_States#New_York#Monteverde_Associates#Avidity_Biosciences#Novartis_AG
Tourmaline Bio, Inc. Shareholder Investigation Launched by M&A Class Action Firm#United_States#New_York#M&A_Class_Action#Novartis_AG#Tourmaline_Bio
Tourmaline Bio, Inc. Shareholder Investigation Launched by M&A Class Action Firm
M&A Class Action Firm investigates Tourmaline Bio's sale to Novartis AG, questioning the fairness of the proposed cash offer to shareholders.
third-news.com
September 15, 2025 at 9:39 PM
Tourmaline Bio, Inc. Shareholder Investigation Launched by M&A Class Action Firm#United_States#New_York#M&A_Class_Action#Novartis_AG#Tourmaline_Bio
April Highlights: Key Health Press Releases Reshaping the Industry Landscape#Crunch_Fitness#Eli_Lilly#Novartis_AG
April Highlights: Key Health Press Releases Reshaping the Industry Landscape
Discover the top health press releases from April, featuring groundbreaking medical studies and significant industry updates from key players like Eli Lilly and Crunch Fitness.
third-news.com
May 9, 2025 at 10:51 AM
April Highlights: Key Health Press Releases Reshaping the Industry Landscape#Crunch_Fitness#Eli_Lilly#Novartis_AG
Regulus Therapeutics to Be Acquired by Novartis AG for Up to $1.7 Billion#USA#San_Diego#Regulus_Therapeutics#farabursen#Novartis_AG
Regulus Therapeutics to Be Acquired by Novartis AG for Up to $1.7 Billion
Regulus Therapeutics has announced its acquisition by Novartis for $7.00 per share, potentially totaling $1.7 billion with contingent rights.
third-news.com
April 30, 2025 at 11:14 AM
Regulus Therapeutics to Be Acquired by Novartis AG for Up to $1.7 Billion#USA#San_Diego#Regulus_Therapeutics#farabursen#Novartis_AG